The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Giotrif



Boehringer Ingelheim International GmbHEU/1/13/879/007-009

Main Information

Trade NameGiotrif
Active SubstancesAfatinib-dimaleate
Dosage FormFilm-coated tablet
Licence HolderBoehringer Ingelheim International GmbH
Licence NumberEU/1/13/879/007-009

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE13 afatinib

Status

License statusAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal products on “restricted” medical prescription, reserved for use in certain specialised areas (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back